Department of Obstetrics and Gynecology, Tampere University Hospital, Finland; Tays Cancer Centre, Tampere University Hospital, Finland.
Department of Obstetrics and Gynecology, Tampere University Hospital, Finland; Faculty of Medicine and Health Technology, Tampere University, Finland; Tays Cancer Centre, Tampere University Hospital, Finland.
Gynecol Oncol. 2022 Jun;165(3):478-485. doi: 10.1016/j.ygyno.2022.03.023. Epub 2022 Apr 6.
To compare survival rates of surgically treated advanced epithelial ovarian cancer patients before and after a programmatic change in surgical approach from standard surgery towards ultra-radical surgery.
247 patients with FIGO stage IIIB-IV ovarian, tubal, and primary peritoneal carcinoma were operated during 2013-2019 either by primary or interval cytoreduction in Tampere University Hospital, Finland. Group 1 (n = 122) patients were operated during 2013 and February 2016. Group 2 patients (n = 125) were operated between March 2016 and March 2019, when a systematic change in surgical approach towards more extensive surgery was implemented.
The complete resection (R0) rate increased significantly from 17.2% (21/122) to 52.0% (65/125) within the study period (p < 0.001). The median progression-free survival (PFS) was 15.6 months vs 19.3 months (p = 0.037), and the median overall survival (OS) was 33.5 months vs 54.5 months in Groups 1 and 2, respectively (p = 0.028). Median OS for stage III patients in Group 1 was 36.1 months (95% CI 27.4-44.8) but could not be reached in Group 2 (p = 0.009). In Stage IV patients, OS was 32.0 months (16.4-47.7) and 39.3 months (24.8-53.8) in Group 1 and 2, respectively (p = 0.691). Multivariable Cox regression analysis revealed that OS was independently affected by the amount of residual tumor and complication grade.
The change of surgical approach towards maximal surgical effort improved both progression-free and overall survival. The survival benefit was unquestionable for stage III patients but did not reach statistical significance in stage IV patients.
比较经程序性手术方式改变,由标准手术转为超根治性手术治疗后,上皮性卵巢癌晚期患者的生存率。
2013 年至 2019 年,在芬兰坦佩雷大学医院对 247 例FIGO 分期为 IIIB-IV 期卵巢、输卵管和原发性腹膜癌患者进行了手术治疗,采用初次或间隔性肿瘤细胞减灭术。第 1 组(n=122)患者于 2013 年和 2016 年 2 月接受手术。第 2 组(n=125)患者于 2016 年 3 月至 2019 年 3 月接受手术,期间手术方式改为更广泛的切除。
研究期间,完全切除(R0)率从 17.2%(21/122)显著提高到 52.0%(65/125)(p<0.001)。无进展生存期(PFS)的中位数为 15.6 个月对 19.3 个月(p=0.037),第 1 组和第 2 组的总生存期(OS)中位数分别为 33.5 个月和 54.5 个月(p=0.028)。第 1 组 III 期患者的中位 OS 为 36.1 个月(95%CI 27.4-44.8),但第 2 组无法达到(p=0.009)。IV 期患者的 OS 分别为 32.0 个月(16.4-47.7)和 39.3 个月(24.8-53.8)(p=0.691)。多变量 Cox 回归分析显示,OS 独立于残余肿瘤量和并发症分级。
手术方式改为最大程度的手术努力,改善了无进展生存期和总生存期。III 期患者的生存获益是毋庸置疑的,但 IV 期患者未达到统计学意义。